Press release
Analytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGene
Protagen Protein Services, a leading global analytic CRO and expert in protein science, and BioAnalytix, a U.S.-based advanced analytics and data analysis firm, combined in April 2019. GeneWerk, with unique capabilities in vector safety, integration site analysis, and bioinformatics, merged into the group in 2021, creating ProtaGene, a portfolio company of Ampersand Capital Partners.
Martin Blüggel, CEO of ProtaGene and the founder of Protagen Protein Services, said: "We are very excited to launch ProtaGene. The track record and reputation of the three legacy entities are individually impressive, and their combination into a single, globally integrated business delivers significant compounded value for our sponsors. Our new scale and breadth of expertise will benefit the impressive list of innovative products we support, both in development and on the market, and ultimately deliver for patients worldwide. We are passionate in our vision to establish ProtaGene as the world"s leading CRO partner in biologics and cell & gene therapy markets."
Kirtland Poss, CEO-US of ProtaGene and the founder of BioAnalytix, added, "Our collective expertise and unwavering delivery in both protein and gene analytics are well established. By combining our capabilities, platforms and knowledge, we can now provide our U.S.-based biopharmaceutical and gene therapy customers advanced access to the broadest analytical offering from discovery to market, from a single vendor relationship."
Annette Deichmann, Senior Vice President of Cell & Gene Therapy at ProtaGene and the cofounder of GeneWerk, said: "We are delighted to embark on this journey, where we will continue to employ our unique expertise and method innovation in cell & gene therapy. Our unique experience in gene analytics - especially integration site analysis, vector purity, vector copy numbers, and bioinformatics analysis for preclinical development and clinical trials - will support many innovators in taking breakthrough therapies to the clinic." ProtaGene also launched a new corporate website at www.protagene.com
About ProtaGene
ProtaGene is a world leading CRO partner for the biopharmaceutical and cell & gene therapy industries. From discovery to product commercialization, ProtaGene provides the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics and cell & gene therapy platforms. A unique combination of protein- and gene-based analytical platforms make ProtaGene the leading analytic service provider in biologics and cell & gene therapy development. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide. Additional information is available at www.protagene.com
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm´s core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com
Company Description
Analytical Excellence-Enabling Tomorrow"s Therapeutics
ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, we provide the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms.
Our deep history of analytical leadership in protein-based therapeutics stems from the merger of Protagen Protein Services in Europe and BioAnalytix in the US. In 2021, GeneWerk"s unique capabilities in vector safety, integration site analysis, and bioinformatics were added to our portfolio, establishing ProtaGene.
Our combined protein- and gene-based analytical platforms make it the leading analytic service provider across the biopharmaceutical and gene and cell therapy development spaces. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide.
Keywords
Biologics, Antibody, Antibodies, Gene, Cell, therapy, Gene and Cell Therapy, Protein, Characterization, CMC, Analytical Excellence
ProtaGene GmbH
Inselwiesenstraße 10
74076 Heilbronn
Germany
Company Description
Analytical Excellence-Enabling Tomorrow"s Therapeutics
ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, we provide the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms.
Our deep history of analytical leadership in protein-based therapeutics stems from the merger of Protagen Protein Services in Europe and BioAnalytix in the US. In 2021, GeneWerk"s unique capabilities in vector safety, integration site analysis, and bioinformatics were added to our portfolio, establishing ProtaGene.
Our combined protein- and gene-based analytical platforms make it the leading analytic service provider across the biopharmaceutical and gene and cell therapy development spaces. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Analytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGene here
News-ID: 2526639 • Views: …
More Releases from ProtaGene GmbH
New Capital Strengthens ProtaGene's Advanced Analytical Leadership in the Biolog …
𝗛𝗘𝗜𝗟𝗕𝗥𝗢𝗡𝗡, 𝗚𝗲𝗿𝗺𝗮𝗻𝘆, 𝗡𝗼𝘃. 𝟮𝟯, 𝟮𝟬𝟮𝟯: ProtaGene GmbH, a leading global contract research organization (CRO) dedicated to advanced analytics for biologics and cell and gene therapies, today announced additional investment from Ampersand Capital Partners.
Given the critical importance of advanced bioanalytics and product characterization for developing increasingly complex therapeutics, Ampersand has invested nearly $40 million within the past year to support ProtaGene's services and capacity expansions. This investment has allowed the organization…
More Releases for Gene
DNA and Gene Cloning Services Market Expands with Growing Focus on Complex Gene …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global DNA and Gene Cloning Services Market by Type of Service Offered (Custom Cloning, Sub-cloning, Gene Synthesis, and Others), Type of Gene (Complex Gene, Standard Gene, and Others), End-User Industry (Pharmaceutical, Academic and R&D, and Biotechnology Companies, and Others)- Market Outlook and Industry Analysis 2034"
The DNA and Gene Cloning Services Market Size is valued…
Evolving Market Trends In The CRISPR Gene Editing Industry: Innovative Gene Ther …
The CRISPR Gene Editing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected CRISPR Gene Editing Market Size During the Forecast Period?
The CRISPR gene editing market has grown exponentially in recent years. It will grow from $2.26 billion in 2024 to $2.88…
Cell and Gene Therapy Market Global Analysis By Type (Cell Therapy, Gene Therapy …
Gene and cell therapy uses genes and cells for the treatment of genetic diseases. Genetic diseases are caused by mutations, or errors in genes which can be passed down from one generation to another. Gene therapy aims to treat diseases by using genetic material, or DNA, to manipulate a patient's cells by replacing, changing or introducing genome into cells- either internally or externally. Cell therapy aims to treat diseases by…
Competitive and Opportunities Analysis of Gene Therapy Market of Gene Therapy Ma …
Global Gene Therapy Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 12.29 billion by 2030 and is anticipated to register a CAGR of 19.8%. Gene therapy means fixing a working gene to an individual who features a damaged gene. The European Commission has approved this method for one particular treatment. The treatment by the merchandise Glybera uses an epidemic to infect muscle cells with…
Genetic Testing Market Size by Growth Opportunities, Top Key Players: GeneDx, In …
Genetic Testing Market Report provides an in-depth analysis of the overall market, The ripple effect of Coronavirus-Covid19 on the market needs to become part of strategy discussions to emerge strong. The report focuses on major key players, production details, their application, countries and also analyzes the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks.
The Top players Covered in report are GeneDx, Invitae, Pathway Genomics,…
Gene Synthesis Market by Top Manufacturers - Gene script, Gene Art (Thermofische …
The "Gene Synthesis Market" report Added by "Big Market Research", enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.
In the Gene Synthesis Market 2018 research report professionals describe the different facets of the industry with a specific goal…
